Risk of valuation losses from securities prices and rising interest rates
First written in FY2016. 12 of 32 entries say "Materialised", first in FY2020-Q1. Latest entry: 2026-11-09.
No other company in this theme has enough history to compare yet.
- 2026-11-09MitigatedResults
「その他有価証券評価差額金 △1,039 △671」
その他有価証券評価差額金のマイナス幅が前年度末の10億39百万円から6億71百万円へ縮小した。 - FY2026MitigatedAnnual report
「Assuming that all risk variables other than interest rates remain constant, and that the benchmark interest rate as of 31 March 2026 increases by 100 basis points (1.00%), the fair value of the net amount, after offsetting the relevant financial assets and financial liabilities, on the asset side would increase by ¥3,760 million. If the benchmark interest rate decreases by 100 basis points (1.00%), the fair value would decrease by ¥3,760 million. No impairment was recognized during the consolidated fiscal year.」
No securities were impaired during the current year, and the valuation difference on other securities improved from a negative ¥1,203 million at the end of the previous fiscal year to a negative ¥1,039 million. Interest-rate sensitivity was disclosed as an increase of ¥3,760 million for a 100-basis-point rise, while the impact of a 10% decline in share prices was stated as ¥829 million. - 2026-05-13OtherResults
「その他有価証券の評価損益は△1,904百万円となり、2025年３月末比165百万円改善しました。」
その他有価証券全体の評価損益は改善した一方、債券の評価損は前年度末の29億67百万円から59億66百万円へ拡大しており、内訳は悪化と改善が併存している。 - FY2026-H1MitigatedAnnual report
「Valuation difference on other securities △1,203 △241 No impairment was recognized during the interim consolidated accounting period.」
The valuation difference on other securities improved from a negative ¥1,203 million at the end of the previous fiscal year to a negative ¥241 million, and no impairment was recognized during the interim period. - FY2025MaterialisedAnnual report
「Impairment losses recognized during the consolidated fiscal year totaled ¥229 million on bonds. Valuation difference on other securities 1,189 △1,203」
Regarding the risk of fluctuations in securities prices and interest rates, in addition to the impairment of equities in the previous year, ¥229 million of bonds were impaired in the current year. The valuation difference on other securities also changed from a positive ¥1,189 million to a negative ¥1,203 million. - FY2025-H1MaterialisedAnnual report
「Impairment losses recognized during the interim consolidated period totaled ¥229 million on bonds.」
Regarding the risks of securities price declines, interest-rate movements and similar factors, an impairment loss of ¥229 million on bonds actually occurred during the interim period, in addition to the previous equity impairment losses. The valuation difference on other securities also decreased from ¥1,189 million to ¥479 million. - FY2024Full-year update to interest-rate sensitivity and continued equity impairmentAnnual report
「Assuming that all risk variables other than interest rates remained constant, and that as of 31 March 2024 the benchmark interest rate had risen by 100 basis points (1.00%), the market value of the net amount of the relevant financial assets after offsetting financial liabilities, on the asset side, was determined to increase by ¥5,656 million. If the benchmark interest rate had fallen by 100 basis points (1.00%), it was determined to decrease by ¥5,656 million. ... Impairment losses recognized during the consolidated fiscal year totaled ¥54 million on equities.」
Sensitivity to a 100-basis-point change in interest rates was disclosed as ¥5,656 million, and the occurrence of ¥54 million in equity impairment losses was confirmed for the full fiscal year. Meanwhile, the valuation difference on other securities improved from negative ¥266 million at the end of the previous fiscal year to ¥1,189 million. - FY2024-Q3Third-quarter improvement in valuation difference and continued equity impairmentAnnual report
「Impairment losses recognized during the third quarter of the consolidated cumulative period totaled ¥54 million on equities. Valuation difference on other securities △ 266 506」
An impairment loss of ¥54 million on equities was also recognized during the cumulative third-quarter period. Meanwhile, the valuation difference on other securities improved from negative ¥266 million at the end of March 2023 to ¥506 million at the end of December 2023. - FY2024-Q2First-half improvement in valuation difference and continued equity impairmentAnnual report
「Impairment losses recognized during the interim consolidated period totaled ¥54 million on equities. Valuation difference on other securities △266 324」
An impairment loss of ¥54 million on equities was also recognized in the first half of fiscal 2023. Meanwhile, the valuation difference on other securities improved from negative ¥266 million at the end of March 2023 to positive ¥324 million, with both a recovery in valuation and impairment disclosed. - FY2024-Q1MaterialisedAnnual report
「Impairment losses recognized during the first quarter of the consolidated cumulative period totaled ¥54 million on equities.」
Regarding the risk of securities price declines and similar factors, an impairment loss of ¥54 million on equities was actually recognized during the first quarter of fiscal 2023. Meanwhile, the valuation difference on other securities improved from negative ¥266 million at the end of the previous fiscal year to ¥536 million. - FY2023WorsenedAnnual report
「Impairment losses recognized during the consolidated fiscal year totaled ¥34 million on equities.」
An impairment loss of ¥34 million on equities was recognized. The valuation difference on other securities also declined from ¥1,284 million in the previous fiscal year to negative ¥266 million, indicating deterioration in valuation. - FY2023-Q3MaterialisedAnnual report
「Total 147,120 153,396 148,885 151,971 1,765 △1,425 Impairment losses recognized during the third quarter of the consolidated cumulative period totaled ¥28 million on equities.」
The valuation difference on other securities decreased from ¥1,765 million at the end of March 2022 to negative ¥1,425 million at the end of December 2022, and an impairment loss of ¥28 million on equities was recognized. The risk of securities price declines and valuation losses continued to materialize. quantified is true and materialized is true. - FY2023-Q2MaterialisedAnnual report
「Impairment losses recognized during the interim consolidated period totaled ¥28 million on equities.」
Regarding the risk of securities price declines and similar factors, an impairment loss of ¥28 million on equities was recognized during the interim consolidated period. The valuation difference on other securities also decreased from ¥1,284 million at the end of March 2022 to negative ¥216 million. quantified is true and materialized is true. - FY2023-Q1First-quarter decrease in valuation difference and no impairment lossesAnnual report
「Total 147,120 148,885 1,765 155,240 155,738 497 No impairment losses were recognized during the first quarter of the consolidated cumulative period.」
The valuation difference on other securities decreased from ¥1,765 million at the end of March 2022 to ¥497 million at the end of June 2022. Meanwhile, no impairment losses were recognized during the first quarter of the consolidated cumulative period. - FY2022MaterialisedAnnual report
「Impairment losses recognized during the consolidated fiscal year totaled ¥73 million on equities.」
Regarding the risk of securities price declines and similar factors, an impairment loss of ¥73 million on equities was recognized for the full fiscal year. The valuation difference on other securities decreased from ¥2,109 million in the previous fiscal year to ¥1,284 million. - FY2022-Q3MaterialisedAnnual report
「Write-downs of equities and other securities ¥19 million ¥73 million」
Regarding the risk of securities price declines and similar factors, write-downs of equities and other securities during the cumulative third-quarter period totaled ¥73 million, up from ¥19 million in the same period of the previous year. Meanwhile, the valuation difference on other securities increased from ¥2,109 million at the end of the previous consolidated fiscal year to ¥2,361 million. - FY2022-Q2Improvement in valuation difference and update to first-half equity impairment resultsAnnual report
「Impairment losses recognized during the interim consolidated period totaled ¥67 million on equities.」
The valuation difference on other securities at the end of September 2021 was ¥2,426 million, up from ¥2,109 million at the end of March 2021. Meanwhile, an impairment loss of ¥67 million on equities was recognized during the interim consolidated period, indicating that the risk of securities price declines continued to materialize. - FY2022-Q1MaterialisedAnnual report
「Write-downs of equities and other securities ¥2 million ¥67 million」
Regarding the risk of securities price declines and similar factors, write-downs of equities and other securities during the first quarter of the consolidated cumulative period totaled ¥67 million, up from ¥2 million in the same period of the previous year. The valuation difference on other securities increased from ¥2,109 million at the end of the previous consolidated fiscal year to ¥2,265 million. - FY2021Improvement in valuation difference and decrease in impairment lossesAnnual report
「Impairment losses recognized during the consolidated fiscal year totaled ¥19 million on equities.」
Impairment losses on equities decreased from ¥173 million in the previous fiscal year to ¥19 million, while the valuation difference on other securities increased from ¥242 million to ¥2,109 million. Meanwhile, the market-value impact of a 100-basis-point rise in interest rates was disclosed as ¥1,746 million. The risk itself remains. - FY2021-Q3Improvement in valuation difference and unchanged impairment amountAnnual report
「Total 131,375 131,695 320 141,193 144,127 2,933 Impairment losses recognized during the third quarter of the consolidated cumulative period totaled ¥19 million on equities.」
The valuation difference on other securities increased from ¥320 million at the end of the previous consolidated fiscal year to ¥2,933 million. Meanwhile, impairment losses on equities during the cumulative third-quarter period totaled ¥19 million, with no additional increase in impairment losses indicated from the previous interim period. - FY2021-Q2MaterialisedAnnual report
「Impairment losses recognized during the interim consolidated period totaled ¥19 million on equities.」
Regarding the risk of securities price declines and similar factors, an impairment loss of ¥19 million on equities was recognized during the interim consolidated period. Meanwhile, the valuation difference on other securities increased from ¥242 million to ¥1,862 million. - FY2021-Q1MitigatedAnnual report
「Write-downs of equities and other securities ¥28 million ¥2 million」
Write-downs of equities and other securities decreased from ¥28 million in the same period of the previous year to ¥2 million in the current quarter. The risk of securities price declines continued to materialize, but the write-down amount for the current quarter was below that of the same period of the previous year. - FY2020MaterialisedAnnual report
「Impairment losses recognized during the consolidated fiscal year totaled ¥173 million on equities.」
Regarding the risk of securities price declines, an impairment loss of ¥173 million on equities was recognized for the full fiscal year. The valuation difference on other securities also decreased from ¥2,522 million to ¥242 million. - FY2020-Q3Slight decrease in valuation difference and continued equity impairmentAnnual report
「Impairment losses recognized during the third quarter of the consolidated cumulative period totaled ¥28 million on equities.」
An impairment loss of ¥28 million on equities was recognized during the cumulative third-quarter period. The valuation difference on other securities decreased slightly from ¥3,501 million at the end of March 2019 to ¥3,488 million. - FY2020-Q2MaterialisedAnnual report
「Impairment losses recognized during the interim consolidated period totaled ¥28 million on equities.」
Regarding the risk of securities price declines and similar factors, an impairment loss of ¥28 million on equities was recognized during the interim consolidated period. The valuation difference on other securities increased from ¥2,522 million at the end of March 2019 to ¥2,620 million. - FY2020-Q1MaterialisedAnnual report
「Impairment losses recognized during the first quarter of the consolidated cumulative period totaled ¥28 million on equities.」
Regarding the risk of securities price declines and similar factors, an impairment loss of ¥28 million on equities was recognized during the first quarter. The valuation difference on other securities also decreased from ¥2,522 million to ¥2,419 million. - FY2019Lower interest-rate sensitivity and decrease in valuation differenceAnnual report
「Assuming that all risk variables other than interest rates remained constant, and that as of 31 March 2019 the benchmark interest rate had risen by 100 basis points (1.00%), the market value of the net amount of the relevant financial assets after offsetting financial liabilities, on the asset side, was determined to decrease by ¥17,636 million. If the benchmark interest rate had fallen by 100 basis points (1.00%), it was determined to increase by ¥17,636 million.」
Sensitivity to a 100-basis-point rise in interest rates was ¥17,636 million, down from the previous fiscal year. Meanwhile, the valuation difference on other securities decreased from ¥3,319 million to ¥2,522 million. - FY2019-Q3WorsenedAnnual report
「Valuation difference on other securities 3,319 2,438」
The valuation difference on other securities decreased from ¥3,319 million at the end of the previous consolidated fiscal year to ¥2,438 million. The balance of securities also decreased by ¥4.34 billion from the end of the previous fiscal year, indicating deterioration in the valuation difference resulting from securities price movements. - FY2019-Q2WorsenedAnnual report
「Valuation difference on other securities 3,000」
The valuation difference on other securities decreased from ¥3,319 million at the end of the previous consolidated fiscal year to ¥3,000 million, while the valuation difference on other securities also decreased by ¥318 million during the interim period. No impairment losses were recognized on securities. - FY2018MitigatedAnnual report
「Assuming that all risk variables other than interest rates remained constant, and that as of 31 March 2018 the benchmark interest rate had risen by 100 basis points (1.00%), the market value of the net amount of the relevant financial assets after offsetting financial liabilities, on the asset side, was determined to decrease by ¥22,779 million. If the benchmark interest rate had fallen by 100 basis points (1.00%), it was determined to increase by ¥22,779 million.」
The decrease in market value resulting from a 100-basis-point rise in interest rates was ¥22,779 million, down from ¥36,319 million in the previous fiscal year. - FY2017WorsenedAnnual report
「Assuming that all risk variables other than interest rates remained constant, and that as of 31 March 2017 the benchmark interest rate had risen by 100 basis points (1.00%), the market value of the net amount of the relevant financial assets after offsetting financial liabilities, on the asset side, was determined to decrease by ¥36,319 million. If the benchmark interest rate had fallen by 100 basis points (1.00%), it was determined to increase by ¥36,319 million.」
The decrease in market value resulting from a 100-basis-point rise in interest rates was quantified as ¥36,319 million. The disclosed sensitivity increased from ¥29,963 million in the previous fiscal year. - FY2016First statedAnnual report
「If market interest rates rise in the future, the value of the bond portfolio held by the Company, including government bonds, may decline, adversely affecting the Company's operating results and financial position.」
The market-value impact of a 100-basis-point rise in interest rates was quantified as a decrease of ¥29,963 million.